Cervical screening test
HPV DNA test to detect the presence of oncogenic High Risk (HR) HPV types known to be associated with a higher risk of developing cervical cancer.
Screening for the HR HPV types in women aged 25-75 years old enables the detection of HR types necessary for the progression of a HPV infection to cervical cancer.
Risk based approach
The HPV test is more sensitive than conventional cytology, so it can be performed less frequently.
Routine asymptomatic women who test negative are Low Risk of developing cervical cancer and can be screened every 5 years.
Asymptomatic women who test positive will have a liquid based cytology (LBC) co-test performed on the same LBC vial. They will be assessed as either Intermediate Risk (repeat 12mths) or Higher Risk (refer to colposcopy) depending on the LBC findings.
Symptomatic women and women with a history of high-grade cervical pathology will have a co-test and risk category assigned according to HPV DNA and LBC findings.
Women with special circumstances may be offered more frequent screening or a single CST prior to age 25 years.
In order to help you better understand the Cervical Screening Test (CST), we have created a range of resources that are available to be downloaded using the links below.
Self-collected HPV test [pdf download]
Request form [pdf download]
Guide for Clinicians [pdf download]
Information for Patients [pdf download]
Flowcharts for 'Pathway for routine cervical screening' [pdf download]
Flowcharts for 'Transition to the renewed National Cervical Screening Program' [pdf download]
Addressing challenges in the new cervical screening program, May 2018 [pdf download]
For further information about the Cervical Screening Test, please contact GynaePath on (02) 9855 6200.